Ontology highlight
ABSTRACT:
SUBMITTER: Cook AD
PROVIDER: S-EPMC5784476 | biostudies-literature | 2018 Feb
REPOSITORIES: biostudies-literature
Cook Andrew D AD Hamilton John A JA
Therapeutic advances in musculoskeletal disease 20180111 2
Mavrilimumab (formerly CAM-3001) is a high-affinity, immunoglobulin G4 monoclonal antibody (mAb) against the granulocyte macrophage colony-stimulating factor (GM-CSF) receptor-α chain. Phase I and II trials in patients with rheumatoid arthritis (RA) treated with mavrilimumab have shown encouraging results with respect to both safety and efficacy. No significant adverse events have so far been noted. The trials have demonstrated significant clinical benefit, meeting primary endpoints. Furthermore ...[more]